Active Ingredient History
Lenvatinib, developed by Eisai Co., is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. Lenvatinib is marketed under the trade name Lenvima, it is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Renal Cell (approved 2015)
Adenocarcinoma (Phase 2)
Adrenocortical Carcinoma (Phase 2)
Allergy and Immunology (Phase 2)
Anemia (Phase 1)
Antineoplastic Agents (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Biomarkers (Phase 2)
Biomarkers, Pharmacological (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 4)
Carcinoma (Phase 2)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Merkel Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Renal Cell (Phase 4)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Catheters (Phase 2)
Central Nervous System Neoplasms (Phase 1)
Chemoembolization, Therapeutic (Phase 1/Phase 2)
Cholangiocarcinoma (Phase 3)
Colorectal Neoplasms (Phase 3)
DNA Mismatch Repair (Phase 2)
Drugs, Investigational (Phase 4)
Endometrial Neoplasms (Phase 4)
Epirubicin (Phase 2)
Esophageal Neoplasms (Phase 3)
Esophageal Squamous Cell Carcinoma (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Female Urogenital Diseases (Phase 2)
Gallbladder Neoplasms (Phase 2)
Genital Neoplasms, Female (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Healthy Volunteers (Phase 1)
Hodgkin Disease (Phase 1)
Immune Checkpoint Inhibitors (Phase 3)
Immunotherapy (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 2)
Kidney Failure, Chronic (Phase 1)
Kidney Neoplasms (Phase 2)
Leiomyosarcoma (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liposarcoma (Phase 1/Phase 2)
Liver Diseases (Phase 1)
Liver Neoplasms (Phase 2)
Liver Transplantation (Phase 3)
Lung Diseases (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Male Urogenital Diseases (Phase 2)
Melanoma (Phase 3)
Mesothelioma (Phase 2)
Multiple Endocrine Neoplasia Type 1 (Phase 2)
Multiple Myeloma (Phase 1)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoadjuvant Therapy (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplasms, Glandular and Epithelial (Phase 2)
Neuroendocrine Tumors (Phase 2)
Oncogene Proteins (Phase 2)
Oncogenes (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 4)
Oxaliplatin (Phase 2)
Pancreatic Neoplasms (Phase 2)
Papillomaviridae (Phase 2)
Pheochromocytoma (Phase 2)
Primary Myelofibrosis (Phase 1)
Radiosurgery (Phase 1/Phase 2)
ras Proteins (Phase 2)
Rectal Neoplasms (Phase 1)
Recurrence (Phase 3)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 2)
Severity of Illness Index (Phase 1)
Sexuality (Phase 2)
Skin Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 2)
Thrombosis (Phase 2)
Thymoma (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Carcinoma, Anaplastic (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Urogenital Diseases (Phase 2)
Urogenital Neoplasms (Phase 2)
Urologic Diseases (Phase 2)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
Vaginal Neoplasms (Phase 1/Phase 2)
Vulvar Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
